TRIALSITEIQ PUBLIC FEASIBILITY SCORECARD · GRADE C

NCT05871970: Safety and Efficacy Study of Intracystic TARA-002 for the Treatment of Lymphatic Malformations in Participants 6 Months to Less Than 18 Years of Age

Sponsor: Protara Therapeutics · Phase: PHASE2 · Area: CARDIOLOGY_METABOLIC · Target Enrollment: 38 pts

Competing Trials Overlap

8 Active Trials

Excess Burn Exposure

$1,460,800

Rescue Site Savings

+$962,800

Unlock Full NCT05871970 Backup Super-Site Packet ($49 One-Time Pass)

Download the complete list of top-decile low-cannibalization clinical sites, verified Principal Investigator (PI) direct emails/phones, and protocol optimization benchmarks.

Download $49 NCT05871970 Rescue Dossier →